{"product_id":"hikma-five-forces-analysis","title":"Hikma Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cphikma faces moderate supplier power and regulatory complexity steady buyer bargaining from institutional clients a balanced threat generics new entrants that together shape its pricing margin outlook.\u003e\u003cpthis brief snapshot only scratches the surface. unlock full porter five forces analysis to explore hikma competitive dynamics market pressures and strategic advantages in detail.\u003e\n\u003c\/pthis\u003e\u003c\/phikma\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI Supplier Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma relies on a concentrated network of active pharmaceutical ingredient (API) manufacturers to support its generic and injectable portfolio, with an estimated 20–30% of complex injectable APIs sourced from fewer than five qualified vendors as of 2025.\u003c\/p\u003e\n\u003cp\u003eWhile many APIs are commoditized, specialized components for complex injectables face high supplier concentration, giving vendors pricing and timing leverage during shortages.\u003c\/p\u003e\n\u003cp\u003eGlobal disruptions in 2020–2023 raised API lead times by ~35% and pushed raw material costs up 12–18%, showing how geopolitical instability amplifies supplier power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet Good Manufacturing Practices and hold FDA or EMA approvals to supply Hikma, and obtaining those certifications costs $0.5–2M and 12–36 months on average, creating a strong lock-in that favors incumbents; switching suppliers thus involves regulatory audits, stability studies, and batch validations that can take 1–3 years and materially raise switching costs beyond simple price differences.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBackward Integration Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHikma has strengthened backward integration by expanding in-house manufacturing and API (active pharmaceutical ingredient) production for key oncology and branded generics since 2020, cutting third-party API buys by an estimated 18% in 2024 and lowering COGS (cost of goods sold) margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Price Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe cost of chemical precursors and energy in pharmaceutical manufacturing follows global commodity trends and inflation, forcing suppliers to pass price rises to manufacturers like Hikma when substitutes are limited.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, European industrial gas and power prices had risen ~18% year-over-year, and MENA logistics bottlenecks pushed freight rates up about 22%, strengthening supplier leverage over input costs.\u003c\/p\u003e\n\u003cp\u003eHikma faces higher COGS risk during shortages of key precursors, reducing margin flexibility and increasing working capital needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnergy price +18% YoY (Europe, 2025)\u003c\/li\u003e\n\u003cli\u003eFreight rates +22% (MENA, 2025)\u003c\/li\u003e\n\u003cli\u003eHigher COGS and working capital pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe production of sterile injectables needs specialized machinery from a few global engineering firms, giving suppliers strong leverage over Hikma’s operations.\u003c\/p\u003e\n\u003cp\u003eThese suppliers’ equipment is essential for meeting regulatory safety and quality standards; disruptions risk batch failures and recall costs—Hikma reported 2024 sterile injectable revenue of about $1.2bn, so uptime matters.\u003c\/p\u003e\n\u003cp\u003eHigh maintenance costs and proprietary spare parts—often 20–40% premium versus generic parts—further raise supplier bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew global suppliers\u003c\/li\u003e\n\u003cli\u003eEssential for compliance and uptime\u003c\/li\u003e\n\u003cli\u003e2024 sterile injectable revenue ≈ $1.2bn\u003c\/li\u003e\n\u003cli\u003eProprietary parts add 20–40% cost premium\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration and cost shocks squeeze Hikma’s injectable margins and working capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-strong power: concentrated API vendors for complex injectables, certified suppliers with $0.5–2M and 12–36 month entry costs, and scarce sterile-equipment makers give vendors pricing and timing leverage; Hikma cut third-party API buys ~18% in 2024 but remains exposed to input-cost shocks (Europe energy +18% YoY, MENA freight +22% by late-2025) that raise COGS and working capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex injectable APIs from ≤5 vendors\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier certification cost\/time\u003c\/td\u003e\n\u003ctd\u003e$0.5–2M \/ 12–36 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHikma third-party API cut (2024)\u003c\/td\u003e\n\u003ctd\u003e−18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope energy YoY (late‑2025)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMENA freight (late‑2025)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile injectable revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key drivers of competition, buyer and supplier power, entry barriers, substitutes, and rivalry specific to Hikma, highlighting disruptive threats and strategic levers that influence its pricing, profitability, and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary tailored to Hikma—quickly spot competitive pressures and relief strategies for pricing, supply, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPO Consolidation in the US\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US, a handful of Group Purchasing Organizations (GPOs) and three large wholesalers consolidate purchasing for over 60,000 hospitals and pharmacies, giving buyers extreme leverage.\u003c\/p\u003e\n\u003cp\u003eThese buyers drive aggressive price competition, routinely pitting generic manufacturers against each other to cut costs by 20–40% on key SKUs.\u003c\/p\u003e\n\u003cp\u003eFor Hikma Pharmaceuticals, this buyer concentration is a leading cause of price erosion in generics and injectables, contributing to a mid-single-digit to low-double-digit revenue decline in affected US product lines in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Tender Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcross MENA, Hikma sells mainly to government health ministries using centralized tenders that cover national formularies; these buyers can command discounts of 20–50% on generics and set multi-year volumes, capturing whole-market demand.\u003c\/p\u003e\n\u003cp\u003eSuch concentrated purchasing gives governments immense bargaining power—losing a single tender can cut country sales by 30–70% for affected SKUs; Hikma must balance low pricing with regulatory quality standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor standard generics, pharmacists and providers switch manufacturers easily based on price and availability, driving down margins; global generic market prices fell ~3% in 2024, pressuring makers like Hikma (FY2024 gross margin 39.8%).\u003c\/p\u003e\n\u003cp\u003eIdentical chemical composition means little brand loyalty, so Hikma competes on price and supply reliability; Hikma reported 95% on-time delivery in 2024, a key retention metric.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing Transparency Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising global demand for healthcare cost containment has expanded pricing transparency and reference pricing; 2024 OECD data shows 28% more countries adopted reference pricing since 2019, pressuring margins on branded and generic drugs.\u003c\/p\u003e\n\u003cp\u003ePayers and insurers now use data-driven benchmarks—real-world price indices and formulary analytics—to cap reimbursements; in 2024 PBM formulary negotiations cut average reimbursed generic prices by ~12% in key markets.\u003c\/p\u003e\n\u003cp\u003eThis shift strengthens buyers: hospitals, governments, and PBMs can challenge Hikma’s pricing, demand lower list prices, higher rebates, or switch to lower-cost suppliers, risking revenue and margin compression.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% more countries with reference pricing since 2019 (OECD, 2024)\u003c\/li\u003e\n\u003cli\u003e~12% cut in average reimbursed generic prices via PBM negotiations (2024)\u003c\/li\u003e\n\u003cli\u003eBuyers gain leverage through real-world price indices and formulary analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement Strategies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHospitals' shift to value-based procurement favors long-term supply reliability over lowest price, letting Hikma leverage its 98% on-time delivery record (2024) to win contracts but also face demands for value-added services.\u003c\/p\u003e\n\u003cp\u003eRequests for services like specialized packaging and vendor-managed inventory raise Hikma’s costs—industry data show VMI implementations can add 1–3% to COGS—but deepen buyer dependence and reduce churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98% on-time delivery (Hikma, 2024)\u003c\/li\u003e\n\u003cli\u003eVMI adds ~1–3% to COGS (industry)\u003c\/li\u003e\n\u003cli\u003eLong-term contracts increase revenue visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ squeeze trims Hikma margins despite strong delivery and VMI cushioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (GPOs, PBMs, hospitals, governments) hold strong leverage over Hikma, driving 20–50% tender discounts and mid-single to low-double-digit US revenue declines in 2024; PBM negotiations cut reimbursed generic prices ~12% (2024) while global generic prices fell ~3% (2024). Hikma’s 95–98% on-time delivery (2024) and VMI services (adds ~1–3% COGS) partially offset switching risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS tender discounts\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMENA tender discounts\u003c\/td\u003e\n\u003ctd\u003e20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHikma on-time delivery\u003c\/td\u003e\n\u003ctd\u003e95–98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM price cuts\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal generic price change\u003c\/td\u003e\n\u003ctd\u003e−3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVMI cost impact\u003c\/td\u003e\n\u003ctd\u003e+1–3% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHikma Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Hikma Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups; the file is fully formatted and ready for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747377000825,"sku":"hikma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hikma-five-forces-analysis.png?v=1772197831","url":"https:\/\/matrixbcg.com\/products\/hikma-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}